The HER2 targeted agent trastuzumab has been shown to be effective and safe in patients with HER2 positive metastatic BC [10–12] and is now established as a standard initial treatment in HER2 positive BC patients [13–15]. This evidence concerns the gene ERBB2 and breast cancer.